Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
84
resultados
Última actualización
22/01/2026 [06:50:00]
Resultados 50 a 75 de 84
Resumen de: CN121337975A
本发明属于生物医药技术领域，公开了一种靶向免疫组织和细胞的脂质纳米颗粒及其制备方法和应用。作为一种靶向脾脏和淋巴结抗原呈递细胞，T细胞等免疫组织和细胞的脂质纳米颗粒。通过使用半乳糖‑甘露糖等靶向分子修饰的PEG脂质并结合免疫刺激剂来增强免疫反应。该颗粒适用于开发高效安全可及性高的人和兽用传染病疫苗，癌症，自身免疫病，高血压等慢性病疫苗，免疫治疗和在T细胞靶向药物递送中作为体内嵌合抗原受体CAR‑T细胞治疗自身免疫，肿瘤、传染病中的应用。其方法通过特定的LNP脂质体组合，稳定的免疫调节分子，辅料和工艺，提升佐剂的稳定性，开发了在4度具有3年稳定期的脂质纳米颗粒佐剂和免疫治疗技术。
Resumen de: CN121337735A
本发明公开了一种卡博替尼肝靶向脂质纳米粒注射剂及其制备方法与应用，属于药物制剂技术领域。该注射剂以质量占比计，由卡博替尼0.8‑1.5%、DSPE‑PEG2000‑半乳糖2.5%‑4.0%、二棕榈酰磷脂酰胆碱35.0%‑42.0%、谷甾醇6.0%‑8.0%、复合冻干保护剂3.0%‑5.0%及余量pH4.0柠檬酸‑柠檬酸钠缓冲液组成，其中复合冻干保护剂为质量比2:1的羟丙基‑环糊精与甘露醇混合物。本发明制剂降低全身毒性，显著提高肝脏及肿瘤部位药物浓度，抑瘤效果优于临床阳性药阿霉素，适用于肝癌、肝转移瘤的治疗，具备较高的应用前景。
Resumen de: CN121342826A
本发明提出了一种ROS响应性R848前药及其制备方法与应用，属于生物医药技术领域。本发明活性氧响应性R848前药包括R848和马来酰亚胺基团，以及连接这两部分的活性氧响应性缩硫酮键，这样的设计可以将该前药偶联在白蛋白分子上，随后与光敏剂Ce6自组装成白蛋白纳米粒，纳米粒在抵达肿瘤部位后，在激光照射肿瘤部位时通过光敏剂在局部产生高浓度活性氧杀伤肿瘤细胞，同时断裂活性氧响应性化学键释放出R848，作用于肿瘤部位的免疫细胞，实现光动力治疗和免疫治疗，并表现出抗肿瘤活性，对肿瘤联合治疗具有重要意义。
Resumen de: CN121337770A
本发明提供了一种槲皮素脂质纳米颗粒制剂及其制备方法与应用，属于药物制剂技术领域。所述的槲皮素脂质纳米颗粒制剂，包括如下组分：脂质和活性剂；所述的活性剂为槲皮素或/和AAT mRNA；所述槲皮素的摩尔比占脂质的5%‑30%；所述的AAT mRNA的质量与总脂质的比值为1/5‑1/50。本发明提供的槲皮素脂质纳米颗粒制剂用于共递送槲皮素和AAT mRNA，巧妙结合了槲皮素的抗炎抗氧化特性、AAT的蛋白酶调节功能以及LNP制剂的高效递送优势，为ALI和COPD等肺部疾病治疗提供了全新思路。
Resumen de: CN121337768A
本发明属于纳米药物递送和刺激响应性制剂技术领域，提供一种GSH响应性白蛋白纳米药物及其制备方法与应用。该方法通过将白蛋白与DBCO‑PEG2K‑NHS连接，再与叠氮基修饰的RAP肽进行点击反应，获得表面功能化的RAP‑PEG2K‑白蛋白；随后利用GSH还原白蛋白分子内二硫键生成巯基，再加入紫杉醇和PADI4抑制剂GSK484后自组装并形成具有交联二硫键的纳米药物。所得纳米药物在肿瘤细胞高GSH环境中可快速解体并释放药物，且通过RAP肽阻断Padi-RAGE信号通路，从而实现化疗增效与抑制化疗诱导转移的双重调控。本发明制备过程温和、无需额外交联剂，所得纳米药物具有良好的稳定性、可控释放特性及显著的抗肿瘤和抗转移潜力。
Resumen de: CN121338009A
本发明属于生物医药技术领域，具体涉及黄酮类化合物在增强脂质纳米颗粒递送核酸分子效率中的应用和方法。旨在解决LNP体内外递送效率受限、毒性风险等问题。本发明以染料木素、光甘草定、野漆树苷、木犀草素、橙皮素、高良姜素或乔松素7种低毒且生物相容的天然化合物为LNP高效表达增强剂，先让化合物与靶细胞共孵育，再加入含核酸分子的LNP。该方案可显著提升LNP介导的基因表达效率，降低细胞毒性，且体内实验证实能优化LNP生物分布、增强靶组织表达，实现LNP安全性与高效性的协同优化。
Resumen de: CN121337007A
本发明属于植物蛋白包埋生物活性物质领域，提供了一种pH驱动协同精氨酸诱导米糠蛋白自组装纳米颗粒包埋脂溶性多酚的方法。通过调节pH促使米糠蛋白自组装形成纳米颗粒，包埋芦丁等脂溶性多酚；利用精氨酸中氨基、羧基、胍基与多酚通过静电、氢键及疏水作用结合，调控蛋白二级/三级结构，增强其与多酚的界面亲和力，改善纳米颗粒溶解性和稳定性。该方法无需有机溶剂，绿色安全，所得米糠蛋白‑芦丁纳米颗粒包埋率超90%，负载量达23.4%，且芦丁在紫外线照射下稳定性良好，适用于生物活性物质的绿色高效包埋。
Resumen de: CN121338010A
本发明涉及一种用于抗肿瘤的脂质体。具体地，本发明提供一种单唾液神经节苷酯用途，用于制备纳米颗粒的纳米材料，所述纳米材料用于消除纳米颗粒的蛋白冠。本发明发现单唾液神经节苷酯作为纳米颗粒的纳米材料，能够消除纳米颗粒的蛋白冠，克服蛋白冠对纳米颗粒和纳米颗表面修饰的配体的掩盖作用。此外，本发明还开发一种对肿瘤具有优异治疗效果的脂质体。
Resumen de: CN121343157A
本发明涉及生物医药技术领域，提供一种基于改性超支化聚赖氨酸(HPL)的核酸递送载体、制备方法和应用，所述改性HPL是通过氨基‑环氧开环反应、Michael加成反应及氨基‑磷戊烷开环反应，分别将1,2‑环氧化合物、丙烯酸酯以及烷基化二氧磷杂环戊烷等小分子化合物引入HPL三维骨架，构建出具有高效转染性能的核酸递送载体。本发明中所述HPL的制备方法简单、价格低廉，是一种生物相容性极好的合成高分子材料。本发明中所述极简一步法的合成策略，一方面可以引入适当长度的疏水链段，从而提高其细胞摄取及跨膜转运能力，另一方面可将HPL上的伯胺转化为仲胺或叔胺，从而提高其内涵体逃逸能力。
Resumen de: CN121337763A
一种功能化益生菌系统，其中包括由如下(A)至(C)组成的复合物1：(A)聚合物载体，所述聚合物载体包括聚合物骨架(A1)和键合在所述聚合物骨架(A1)上的苯硼酸端基(A2)，所述聚合物骨架(A1)为透明质酸或其盐中的至少一种；(B)多酚类P2X7抑制剂；和，(C)益生菌；其中，所述(A)和(B)形成复合物2，所述复合物2在全部或至少部分所述益生菌表面形成一层功能修饰层。本发明的功能化益生菌系统，具有P2X7抑制性能和高肠道定植效率，能够抗炎、调节机体免疫以及调控患者肠道菌群，适用于治疗溃疡性结肠炎等炎症性肠病。
Resumen de: CN121338044A
本发明公开了一种用于视网膜递送mRNA的脂质纳米颗粒及其制备方法和应用。所述脂质纳米颗粒包含可电离脂质、中性磷脂、胆固醇和PEG化脂质；其中，所述可电离脂质由SM‑102和NT‑O14B组成；SM‑102、NT‑O14B、中性磷脂、胆固醇和PEG化脂质之间的摩尔比为（59.5‑63）：（7‑10.5）：（8‑12）：（16.4‑20.6）：（1.4‑1.6）。与经典LNP配方相比，本发明提供的LNP能够高效递送mRNA至视网膜，并通过小窝蛋白介导的内吞和巨胞饮途径被视网膜色素上皮细胞特异性摄取。体内外实验证实，该LNP可显著提高mRNA在视网膜中的递送效率和功能性蛋白表达水平，且生物相容性良好。本发明为遗传性视网膜疾病（如Leber先天性黑朦）的mRNA治疗提供了一种高效、安全的非病毒递送系统。
Resumen de: CN121337764A
本发明公开了一种具有骨靶向性负载连翘酯苷A的外泌体及其制备方法和应用，涉及生物医药技术领域，制备方法，包括以下步骤：分离培养骨髓间充质干细胞，并通过分子克隆技术过表达GLG1得到GLG1‑BMSCs；通过超速离心法收集GLG1‑BMSCs的外泌体GLG1‑Exos；通过超声法联合挤压法将连翘酯苷A装载入外泌体得到GLG1‑Exos‑FTA。本发明负载中医药活性成分连翘酯苷A，将连翘酯苷A靶向性地递送到骨髓，达到预防和改善糖尿病骨质疏松的作用；其靶向性作用能够增强连翘酯苷A的生物利用度，同时增加抗糖尿病骨质疏松的疗效。实验表明，GLG1‑Exos‑FTA的连翘酯苷A装载率达36.9%，粒径分布峰值为122.4 nm，具备典型外泌体特征和骨靶向性，能显著改善糖尿病骨质疏松小鼠的骨微结构。
Resumen de: WO2024148364A1
Embodiments of the invention include methods of treating conditions that are ameliorated by stimulating an immune response. In aspects, the methods include injection of mesoporous silica rods (MSRs) at or near an affected tissue. The MSRs can include a cytokine (e.g., IL-2 or IL-12) and/or an adjuvant. The MSRs can induce an innate immune response to treat cancer, infection and other ailments. The methods can include administering an additional medicament such as an immune checkpoint inhibitor.
Resumen de: US20260014094A1
A method is provided for producing a composition that includes a nanoparticle with at least one nucleic acid and at least one ionizable lipid. The method includes introducing a first composition that includes the at least one nucleic acid and a second composition that includes the at least one ionizable lipid into at least one reactor. The first composition and the second composition are introduced at a first flow rate and a second flow rate, respectively, therefore generating the nanoparticle in a reaction mixture. The method further includes filtering the nanoparticle from the reaction mixture via a single-pass tangential flow filter at a feed flux to provide a retentate, to produce the composition. The method may also include filtering the retentate through a sterile filtration membrane.
Resumen de: WO2026013203A1
The present invention relates to lipid nanoparticles (LNPs) comprising vitamin A or a vitamin A derivative. The LNPs according to the present invention show an improved stability and nucleic acid delivery efficacy.
Resumen de: US20260014091A1
Disclosed herein are compositions and methods of making and use thereof. For example, disclosed herein are pharmaceutical compositions comprising: a plurality of redox-responsive disulfide nanoparticles; and a tyrosine kinase inhibitor encapsulated within each of the redox-responsive disulfide nanoparticles. Also disclosed herein are methods of treating or preventing an ocular injury, disease, or disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a plurality of redox-responsive disulfide nanoparticles and/or any of the pharmaceutical compositions disclosed herein to the subject.
Resumen de: US20260014089A1
The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.
Resumen de: US20260014175A1
A pharmaceutical composition in the form of a compressed tablet for oral administration. The composition has an intragranular portion including a first porous solid carrier with a physiologically acceptable salt that is soluble in gastric fluid/an acidic aqueous media, and a self-nanoemulsifying drug delivery system (SNEDDS) adsorbed on the carrier. The SNEDDS includes: at least one cannabinoid; one or more solubilizing agents selected from physiologically acceptable organic compounds including: alcohols C8-C18, cyclic alcohols, aromatic alcohols, glycerides, polyethylene glycols, polyethylene glycol esters, aromatic esters, phenols, tocopherols, phospholipids, polyoxylglycerides, or polyoxyethylene stearates; one or more emulsifying agents selected from physiologically acceptable nonionic surfactants; and one or more carrier oils. The composition has an extragranular portion including: an optional second porous solid carrier including a physiologically acceptable salt that is soluble in gastric fluid/an acidic aqueous media; one or more disintegrants; one or more diluents; and one or more lubricants.
Resumen de: US20260014088A1
The present invention relates to lipid nanoparticles for the delivery of proteins and, specifically, to lipid nanoparticles for the intracellular or in vivo delivery of various medicinal proteins such as therapeutic proteins or enzymes for enzyme replacement therapy (ERT). The present invention can be advantageously used for the treatment and prevention of various diseases, including lysosomal storage disorders, by stably and effectively delivering various proteins such as therapeutic proteins or ERT enzymes into cells through lipid nanoparticles.
Resumen de: US20260014085A1
Described herein are milk exosomes and uses thereof. In some embodiments, the milk exosomes are capable of targeting an injury site or a cancer cell or population thereof. The milk exosomes can contain an exogenous cargo. Described herein are formulations containing the milk exosomes, and optionally, a targeting agent, such as IgG or stimulation of ATP concentration, and/or ADP. Also described herein are methods of delivering a cargo to a target.
Resumen de: US20260014075A1
The present disclosure relates to a novel ionizable lipid containing a biodegradable ester bond. The ionizable lipid containing an ester bond, according to the present disclosure, stably delivers an anionic drug when prepared into lipid nanoparticles, and exhibits an excellent effect, in particular, in delivering nucleic acids, and thus can be effectively used in related technical fields such as lipid nanoparticle-mediated gene therapy.
Resumen de: US20260014078A1
An extracellular vesicle includes an exogenous therapeutic component. The exogenous therapeutic component can include a therapeutic polypeptide, a polynucleotide that encodes a therapeutic polypeptide, a therapeutic nucleic acid, or a therapeutic agent. In some embodiments, the extracellular vesicle includes an exosome or purified exosome product (PEP).
Resumen de: US20260014077A1
Disclosed are nanoparticle preparations including a nucleic acid agent, a nucleic acid carrier, a metal salt, a polyethylene glycol (PEG)-lipid, a phospholipid, and a cholesterol or its derivative. Also provided are preparation methods and methods for treating or preventing a condition in a subject using such a nanoparticle preparation.
Resumen de: US20260014076A1
A preparation of PEGylated solid lipid core nanocarriers (SLN) is loaded with at least one drug for delivery to a subject. SLNs having a small size, neutral charge, and high drug encapsulation efficiency are formed. PEGylation improves SLN permeability without hindering cellular uptake, particularly permeability of nasal mucous for intranasal delivery. PEGylated SLNs are suitable for intranasal, inhaled, oral or injected drug delivery. Exemplary formulations include a combined antiretroviral therapy (cART) designed to cross the blood-brain barrier and treat neuroAIDS.
Nº publicación: WO2026015822A1 15/01/2026
Solicitante:
NITTO DENKO CORP [JP]
NITTO DENKO CORPORATION
Resumen de: WO2026015822A1
A cationic lipid, a lipid nanoparticle containing the cationic lipid, and a method of delivering a nucleic acid encapsulated in the lipid nanoparticle to a cell or a subject.
BOPI
Sede Electrónica
